Literature DB >> 24770952

Prognostic factors that govern localized synovial sarcoma: a single institution retrospective study on 51 patients.

Sameer Yaser1, Samer Salah, Marwa Al-Shatti, Areej Abu-Sheikha, Ahmad Shehadeh, Iyad Sultan, Ahmad Salem, Maher Sughayer, Shaymaa Al-Loh, Abdelatif Al-Mousa.   

Abstract

Synovial sarcoma is a rare type of sarcoma with poor prognosis. Data on relevant prognostic factors are inconsistent. The objective of this study was to determine the independent prognostic factors that govern local recurrence, distant metastasis and overall survival. A retrospective analysis of 51 patients treated for localized synovial sarcoma at a single institution by a multidisciplinary/multimodality approach over a period of 12 years. Patients, tumor and treatment characteristics were collected including age, sex, tumor site, location, depth, size, status of margins, histology subtype and involvement of bone or lymph nodes. Type of surgery, adjuvant chemotherapy and radiotherapy were also examined. The endpoints analyzed were local recurrence-free survival (LRFS), metastasis-free survival (MFS) and overall survival (OS). Median age of patients was 26 years (range 3-64 years) with 73 % above the age of 20 year. All patients received surgery, 57 % received adjuvant radiotherapy and 45 % adjuvant chemotherapy. The median survival was 111 months, and 5-year OS was 73 %. Deep seatedness of the tumor was linked to OS as the only independent risk factor. Twelve patients had local recurrence, and the 5-year LRFS was 61 %. Multivariate analysis determined negative margins and adjuvant radiotherapy as independent predicting factors for LRFS. Five-year MFS was 48 %; multivariate analysis identified monophasic subtype and site other than lower extremity as the only independent factors associated with inferior MFS. The most important factors that govern LRFS and MFS are negative margins and adjuvant radiotherapy for LRFS and tumor histology and site for MFS, while deep seatedness of the tumor is the sole independent factor that governs OS.

Entities:  

Mesh:

Year:  2014        PMID: 24770952     DOI: 10.1007/s12032-014-0958-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  37 in total

Review 1.  Evidence-based recommendations for local therapy for soft tissue sarcomas.

Authors:  Peter W T Pisters; Brian O'Sullivan; Robert G Maki
Journal:  J Clin Oncol       Date:  2007-03-10       Impact factor: 44.544

2.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.

Authors:  S Frustaci; F Gherlinzoni; A De Paoli; M Bonetti; A Azzarelli; A Comandone; P Olmi; A Buonadonna; G Pignatti; E Barbieri; G Apice; H Zmerly; D Serraino; P Picci
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

3.  Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities.

Authors:  P W Pisters; D H Leung; J Woodruff; W Shi; M F Brennan
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

4.  Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.

Authors:  Marc Ladanyi; Cristina R Antonescu; Denis H Leung; James M Woodruff; Akira Kawai; John H Healey; Murray F Brennan; Julia A Bridge; James R Neff; Frederic G Barr; Jeffrey D Goldsmith; John S J Brooks; John R Goldblum; Syed Z Ali; Janet Shipley; Colin S Cooper; Cyril Fisher; Björn Skytting; Olle Larsson
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

5.  Descriptive epidemiology of soft tissue sarcomas in Vaud, Switzerland.

Authors:  F Levi; C La Vecchia; L Randimbison; V C Te
Journal:  Eur J Cancer       Date:  1999-11       Impact factor: 9.162

6.  Synovial sarcoma: identification of low and high risk groups.

Authors:  P Bergh; J M Meis-Kindblom; F Gherlinzoni; O Berlin; P Bacchini; F Bertoni; B Gunterberg; L G Kindblom
Journal:  Cancer       Date:  1999-06-15       Impact factor: 6.860

7.  Synovial sarcoma in children and adolescents. A report from the Kiel Pediatric Tumor Registry.

Authors:  D Schmidt; P Thum; D Harms; J Treuner
Journal:  Cancer       Date:  1991-03-15       Impact factor: 6.860

8.  SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.

Authors:  A Kawai; J Woodruff; J H Healey; M F Brennan; C R Antonescu; M Ladanyi
Journal:  N Engl J Med       Date:  1998-01-15       Impact factor: 91.245

9.  Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Authors:  V Bramwell; J Rouesse; W Steward; A Santoro; H Schraffordt-Koops; J Buesa; W Ruka; J Priario; T Wagener; M Burgers
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

Review 10.  Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases.

Authors:  A M Mandard; J F Petiot; J Marnay; J C Mandard; J Chasle; E de Ranieri; P Dupin; P Herlin; J de Ranieri; A Tanguy
Journal:  Cancer       Date:  1989-04-01       Impact factor: 6.860

View more
  7 in total

1.  Beclin1 overexpression suppresses tumor cell proliferation and survival via an autophagy‑dependent pathway in human synovial sarcoma cells.

Authors:  Jialin Zhu; Yongsong Cai; Ke Xu; Xiaoyu Ren; Jian Sun; Shemin Lu; Jinghong Chen; Peng Xu
Journal:  Oncol Rep       Date:  2018-07-25       Impact factor: 3.906

2.  The value of multidisciplinary team (MDT) management in the diagnosis and treatment of primary intrathoracic synovial sarcomas: a single-center experience.

Authors:  Huayu He; Lin Yang; Yue Peng; Li Liu; Lei Liu; Qi Xue; Shugeng Gao
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

3.  Clinical Significance and Risk Factors of Local Recurrence in Synovial Sarcoma: A Retrospective Analysis of 171 Cases.

Authors:  Hongqiang Zhang; Wending Huang; Qi Feng; Wei Sun; Wangjun Yan; Chunmeng Wang; Jianing Zhang; Kai Huang; Lin Yu; Xinglong Qu; Yong Chen
Journal:  Front Surg       Date:  2022-01-13

4.  Soft Tissue Sarcomas: A 16-Year Experience of a Tertiary Referral Hospital in North Jordan.

Authors:  Mohammed S Alorjani; Ismail I Matalka; Mahmoud A Alfaqih; Rami A Jahmani; Belal S Alsinglawi; Faisal M Nimri; Mohammad I Matalka; Samir S Amr
Journal:  Medicina (Kaunas)       Date:  2022-01-27       Impact factor: 2.430

5.  Efficacy of perioperative chemotherapy for synovial sarcoma: a retrospective analysis of a Nationwide database in Japan.

Authors:  Gang Xu; Hisaki Aiba; Norio Yamamoto; Katsuhiro Hayashi; Akihiko Takeuchi; Shinji Miwa; Takashi Higuchi; Kensaku Abe; Yuta Taniguchi; Yoshihiro Araki; Shiro Saito; Kenichi Yoshimura; Hideki Murakami; Hiroyuki Tsuchiya; Akira Kawai
Journal:  BMC Cancer       Date:  2021-07-03       Impact factor: 4.430

6.  Age as an independent prognostic factor for survival of localised synovial sarcoma patients.

Authors:  Myrella Vlenterie; Vincent K Y Ho; Suzanne E J Kaal; Richelle Vlenterie; Rick Haas; Winette T A van der Graaf
Journal:  Br J Cancer       Date:  2015-11-10       Impact factor: 7.640

7.  The effect of adjuvant therapies on long-term outcome for primary resected synovial sarcoma in a series of mainly children and adolescents.

Authors:  Monika Scheer; Christian Vokuhl; Sebastian Bauer; Jörg Fuchs; Steffan Loff; Beate Timmermann; Marc Münter; Anton George Henssen; Bernarda Kazanowska; Felix Niggli; Ruth Ladenstein; Gustaf Ljungman; Ewa Koscielniak; Thomas Klingebiel
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-17       Impact factor: 4.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.